In a dormant state, cancer cells survive chemotherapy leaving the opportunity for cancer cell relapse and metastasis ultimately leading to patient death. A novel aminoglycoside-based hydrogel ‘Amikagel’ developed in Dr. Rege’s lab serves as a platform for a 3D tumor microenvironment (3DTM) mimicking cancer cell dormancy and relapse. Six Amikagels of varying mechanical stiffness and adhesivities were synthesized and evaluated as platforms for 3DTM formation through cell viability and cell cycle arrest analyses. The impact of fetal bovine serum concentration and bovine serum albumin concentration in the media were studied for their impact on 3DTM formation. These experiments allow us to identify the best possible Amikagel formulation for 3DTM.

Plasmid DNA (pDNA) purification has been extensively investigated for various biological and biochemical applications such as transfection, polymerase chain reaction and DNA therapeutics. In the previous paper, we have described the synthesis, characterization and evaluation of microbeads (“Amikabeads”) derived from aminoglycoside amikacin for pDNA binding via anion-exchange chromatography. Here, we investigated the pDNA binding performance of conjugating Amikabeads with two highly specific DNA binding ligands via minor groove hydrophobic interaction. The pDNA maximum binding capacity of doxorubicin drug-conjugated Amikabeads (“doxo-beads”) was found out to be 429 μg pDNA/ mg of doxo-beads with a Langmuir constant of 8.21*10-4 L/mg, whereas the binding performance of berenil drug-conjugated "mikabeads (“berenil-beads”) was 142 μg pDNA/mg of berenil-beads with a adsorption constant of 4.71*10-5 L/mg. In addition, the desorption percentage of doxo-beads and berenil-beads was obtained as 52% and 41%, respectively. Our results indicate that by conjugating with highly specific DNA binding ligands, Amikabeads-drug complex enhances the pDNA binding performance and contains a promising potential for future applications in biotechnology field.

Relapse after tumor dormancy is one of the leading causes of cancer recurrence that ultimately leads to patient mortality. Upon relapse, cancer manifests as metastases that are linked to almost 90% cancer related deaths. Capture of the dormant and relapsed tumor phenotypes in high-throughput will allow for rapid targeted drug discovery, development and validation. Ablation of dormant cancer will not only completely remove the cancer disease, but also will prevent any future recurrence. A novel hydrogel, Amikagel, was developed by crosslinking of aminoglycoside amikacin with a polyethylene glycol crosslinker. Aminoglycosides contain abundant amount of easily conjugable groups such as amino and hydroxyl moieties that were crosslinked to generate the hydrogel. Cancer cells formed 3D spheroidal structures that underwent near complete dormancy on Amikagel high-throughput drug discovery platform. Due to their dormant status, conventional anticancer drugs such as mitoxantrone and docetaxel that target the actively dividing tumor phenotype were found to be ineffective. Hypothesis driven rational drug discovery approaches were used to identify novel pathways that could sensitize dormant cancer cells to death. Strategies were used to further accelerate the dormant cancer cell death to save time required for the therapeutic outcome.

Amikagel’s properties were chemo-mechanically tunable and directly impacted the outcome of tumor dormancy or relapse. Exposure of dormant spheroids to weakly stiff and adhesive formulation of Amikagel resulted in significant relapse, mimicking the response to changes in extracellular matrix around dormant tumors. Relapsed cells showed significant differences in their metastatic potential compared to the cells that remained dormant after the induction of relapse. Further, the dissertation discusses the use of Amikagels as novel pDNA binding resins in microbead and monolithic formats for potential use in chromatographic purifications. High abundance of amino groups allowed their utilization as novel anion-exchange pDNA binding resins. This dissertation discusses Amikagel formulations for pDNA binding, metastatic cancer cell separation and novel drug discovery against tumor dormancy and relapse.